$14.28
+0.53 (+3.85%)
Open$13.75
Previous Close$13.75
Day High$14.90
Day Low$13.75
52W High$44.54
52W Low$30.30
Volume—
Avg Volume644.8K
Market Cap208.96M
P/E Ratio41.14
EPS$0.81
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+185.3% upside
Current
$14.28
$14.28
Target
$40.74
$40.74
$28.14
$40.74 avg
$50.62
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 84.57M | 86.26M | 76.53M |
| Net Income | -20,699,385 | -25,319,011 | -23,908,785 |
| Profit Margin | -24.5% | -29.4% | -31.2% |
| EBITDA | -24,990,141 | -25,196,528 | -24,930,968 |
| Free Cash Flow | -20,292,095 | -20,848,476 | -17,728,438 |
| Rev Growth | +3.2% | +20.0% | +0.5% |
| Debt/Equity | 0.58 | 0.68 | 0.63 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.03 | -0.25% | 139.7 | 43.84B |